#COVAX

  • Benefits of AstraZeneca COVID-19 vaccine outweigh risks: WHO

    The World Health Organization's Strategic Advisory Group of Experts (SAGE) said on Wednesday that the benefits of the AstraZeneca/Oxford University COVID-19 vaccine outweigh the potential risks.

    "The data reviewed by WHO support the conclusion that the known and potential benefits of AZD1222 outweigh the known and potential risk," SAGE said in a set of interim recommendations.

  • China addresses disparities in COVID-19 vaccine distribution

    -- In the face of production shortfalls across the world, some rich countries are hoarding vaccines, leaving poorer ones defenseless in the face of the deadly pathogen. As of mid-January, high-income countries, which represent only 16 percent of the world's population, had taken 60 percent of available doses.

    -- Experts said closing the immunity gap is not only about morality and conscience, but also the key to stopping the pandemic by cutting risk of more new variants.

  • China at Davos: A steady voice for multilateralism

    “It was the best of times, it was the worst of times.” Four years ago in Davos, President Xi Jinping quoted this famous line of Charles Dickens to describe a world fraught with contradictions. He observed, “On the one hand, with growing material wealth and advances in science and technology, human civilization has developed as never before. On the other hand, frequent regional conflicts, global challenges like terrorism and refugees, as well as poverty, unemployment and widening income gap have all added to the uncertainties of the world.”

  • China to push ahead equitable distribution of COVID-19 vaccines

    China announced earlier that it would provide 10 million doses of COVID-19 vaccines to the global vaccine sharing initiative COVAX to meet the urgent needs of developing countries, showing a strong sense of responsibility at such a critical moment.

    It is another major move of China to promote equitable distribution of COVID-19 vaccines, push ahead international anti-pandemic cooperation and put into practice the vision of building a community of common health for mankind.

  • COVID antibodies are transferred from pregnant women to their babies

    The findings of a recent study suggested that antibodies that help in guarding against the COVID-19 virus are transferred from mothers to their babies while in the womb.

    This discovery, published in the 'American Journal of Obstetrics and Gynecology', adds to growing evidence that suggests that pregnant women who generate protective antibodies after contracting the coronavirus often convey some of that natural immunity to their fetuses.

  • COVID-19: Health worker death toll rises to at least 17,000 as organizations call for rapid vaccine rollout

    At least 17,000 health workers have died from COVID-19 over the last year, said Amnesty International, Public Services International (PSI) and UNI Global Union in a new analysis, as the organizations called for urgent action to speed up the vaccination of millions of frontline health workers around the world. 

  • MP Mari Rantanen questions Finnish government on delayed second dose of Pfizer/BioNTech vaccine

    The Finnish Institute for Health and Welfare gave a recommendation to delay the administration of second dose of all Covid-19 vaccinations to 12 weeks after the first administration. BioNTech, the German manufacturer of the vaccine to be procured in Finland, has warned that the efficacy of the vaccine is not guaranteed if the second dose is delayed by more than three weeks. Member of parliament Mari Rantanen made a parliamentary question to the Finnish government, asking the scientific basis for the recommendation.

  • Oxford-AstraZeneca vaccine developers claim that it reduces COVID-19 transmission

    As per a report by developers of the Oxford-AstraZeneca coronavirus vaccine on Sunday, claimed that it can reduce the transmission of COVID-19 virus, reported The Washington Post.

    In a preprint of an article under review at the Lancet medical journal, the Oxford University vaccine developers report that was based on follow-up studies of their clinical trials found the vaccine safe and effective, there is also "the potential for the vaccine to reduce transmission of the virus".

  • Pfizer, BioNTech begin testing of third dose against new COVID-19 variants

    Pfizer and its partner BioNTech on Thursday said that they have begun to test how well the third dose of their authorised vaccine stacks up against new coronavirus variants.

    The study will evaluate up to 144 Phase 1 participants in two age cohorts, 18-55 and 65-85 years of age.

  • Researchers shed light on why COVID-19 vaccine distribution methods fall short, 3 ways to improve them

    Several proposals have emerged on how to distribute the COVID-19 vaccine, but they fall short in ensuring that the vaccine is distributed fairly. A team of researchers suggests three ways to more fairly and effectively distribute the vaccine so that people in poor countries get the vaccine as soon as possible.

  • Russia's Sputnik V COVID-19 vaccine 91.6 per cent effective: Lancet

    Russian's Sputnik V is 91.6 per cent effective at protecting people from COVID-19, according to the result of an interim analysis of the phase 3 trials published by the journal Lancet on Tuesday.

     "In the interim efficacy analysis of the randomized, double-blind, placebo-controlled clinical trial, where data on 19,866 volunteers were included in the efficacy analysis (14,964 of whom received the vaccine and 4,902 the placebo),

Partners